- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02854436
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)
September 12, 2023 updated by: Janssen Research & Development, LLC
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter and open-label (participants and researchers are aware of the treatment that participants are receiving) study that consists of 4 phases: a Prescreening Phase for biomarker evaluation only, a Screening Phase, a Treatment Phase (Cycle 1 Day 1 and will continue until the study drug is discontinued), a Follow-up Phase (every 3 months after end of treatment visit), and a Long-term Extension Phase (until participants no longer derive benefit from treatment or until further notification on different means of study treatment).
Participants will be monitored for safety during the study period, and up to 30 days after the last dose of study drug.
Study Type
Interventional
Enrollment (Actual)
289
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Camperdown, Australia
-
Darlinghurst, Australia
-
East Albury, Australia
-
Kurralta Park, Australia
-
Macquarie University, Australia
-
Melbourne, Australia
-
Murdoch, Australia
-
Port Macquarie, Australia
-
Randwick, Australia
-
Wahroonga, Australia
-
-
-
-
-
Aalst, Belgium
-
Brussel, Belgium
-
Charleroi, Belgium
-
Gent, Belgium
-
Haine-Saint-Paul, La Louviere, Belgium
-
Hasselt, Belgium
-
Kortrijk, Belgium
-
Liège, Belgium
-
Namur, Belgium
-
Ottignies, Belgium
-
Wilrijk, Belgium
-
-
-
-
-
Barretos, Brazil
-
Belo Horizonte, Brazil
-
Curitiba, Brazil
-
Fortaleza, Brazil
-
Ijui, Brazil
-
Itajai, Brazil
-
Joinville, Brazil
-
Natal, Brazil
-
Salvador, Brazil
-
Sao Paulo, Brazil
-
-
-
-
-
Quebec, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
Ontario
-
Oshawa, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
-
Aarhus N., Denmark
-
Copenhagen N, Denmark
-
Herlev, Denmark
-
Odense C, Denmark
-
-
-
-
-
Avignon Cedex 9, France
-
Besancon, France
-
Caen, France
-
Lyon, France
-
Nice Cedex 2, France
-
Paris, France
-
Reims, France
-
Strasbourg, France
-
Villejuif Cedex, France
-
-
-
-
-
Beer-Sheva, Israel
-
Haifa, Israel
-
Kfar Saba, Israel
-
Ramat Gan, Israel
-
Zrifin, Israel
-
-
-
-
-
Seoul, Korea, Republic of
-
-
-
-
-
Alkmaar, Netherlands
-
Amsterdam, Netherlands
-
Groningen, Netherlands
-
Maastricht, Netherlands
-
Rotterdam, Netherlands
-
-
-
-
-
Moscow, Russian Federation
-
Omsk, Russian Federation
-
Tomsk, Russian Federation
-
-
-
-
-
Barcelona, Spain
-
Córdoba, Spain
-
Madrid, Spain
-
Málaga, Spain
-
Pozuelo de Alarcon, Spain
-
Santander, Spain
-
Santiago de Compostela, Spain
-
Sevilla, Spain
-
Valencia, Spain
-
-
-
-
-
Göteborg, Sweden
-
Lund, Sweden
-
Stockholm, Sweden
-
Umeå, Sweden
-
-
-
-
-
Kaohsiung, Taiwan
-
Taichung, Taiwan
-
Tainan, Taiwan
-
Taipei, Taiwan
-
Taoyuan County, Taiwan
-
-
-
-
-
Blackburn, United Kingdom
-
Bristol, United Kingdom
-
Cardiff, United Kingdom
-
Exeter, United Kingdom
-
London, United Kingdom
-
Preston, United Kingdom
-
-
-
-
Arizona
-
Tucson, Arizona, United States
-
-
California
-
Los Angeles, California, United States
-
Riverside, California, United States
-
Sacramento, California, United States
-
-
Colorado
-
Aurora, Colorado, United States
-
Denver, Colorado, United States
-
-
Illinois
-
Evanston, Illinois, United States
-
-
Kentucky
-
Danville, Kentucky, United States
-
Louisville, Kentucky, United States
-
-
Louisiana
-
New Orleans, Louisiana, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Detroit, Michigan, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New York
-
New York, New York, United States
-
-
North Carolina
-
Durham, North Carolina, United States
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Virginia
-
Charlottesville, Virginia, United States
-
Fairfax, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Wisconsin
-
Madison, Wisconsin, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is excluded)
- Received a taxane-based chemotherapy for the treatment of metastatic prostate cancer with evidence of disease progression on or after treatment, or discontinued from a taxane-based chemotherapy due to an adverse event
- Received a second-generation or later androgen receptor (AR)-targeted therapy (for example, abiraterone acetate plus prednisone, enzalutamide, apalutamide) for the treatment of metastatic prostate cancer with evidence of disease progression or non-metastatic castration-resistant prostate cancer with evidence of subsequent metastasis
- Biomarker-positive by at least one of the following criteria: (a) Biallelic deoxyribonucleic acid (DNA)-repair anomaly based on a sponsor validated blood or tissue assay; (b) Germline pathogenic Breast Cancer gene (BRCA) 1 or BRCA2 by any test (somatic local results must be confirmed as positive by the sponsor-validated assay before dosing)
- Progression of metastatic prostate cancer in the setting of castrate levels of testosterone or history of bilateral orchiectomy at study entry
Exclusion Criteria:
- Prior treatment with a poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor
- Prior platinum-based chemotherapy for the treatment of prostate cancer
- Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
- Symptomatic or impending cord compression
- Symptomatic brain metastases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Niraparib
Participants will receive 300 milligram (mg) niraparib (3 capsules*100 mg) orally once daily.
|
Participants will receive 300 mg niraparib (3 capsules*100 mg) orally once daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation
Time Frame: Up to 52 months
|
ORR defined as percentage of participants with BRCA DNA-repair anomalies and measurable disease whose best response is either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and with no evidence of bone progression per Prostate Cancer Working Group 3 (PCWG3) criteria.
|
Up to 52 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Non-Breast Cancer Gene (BRCA) Mutation
Time Frame: Up to 52 months
|
ORR defined as percentage of participants with BRCA deoxyribonucleic acid (DNA)-repair anomalies and measurable disease whose best response is either CR or PR per RECIST 1.1 and with no evidence of bone progression per PCWG3 criteria.
|
Up to 52 months
|
Circulating Tumor Cells (CTC) Response Rate
Time Frame: At 8 weeks post-baseline
|
CTC response rate was defined as the percentage of participants with CTC equals to (=) 0 per 7.5 milliliter (mL) blood at 8 weeks post-baseline in participants with baseline CTC greater than (>) 0.
|
At 8 weeks post-baseline
|
Overall Survival (OS)
Time Frame: Up to 52 months
|
OS is defined as time from enrollment to death from any cause.
|
Up to 52 months
|
Radiographic Progression-Free Survival (rPFS)
Time Frame: Up to 52 months
|
rPFS was defined as time from enrollment to radiographic progression or death from any cause, whichever occurred first.
Radiographic progression was evaluated per RECIST 1.1 criteria for soft tissue disease and per PCWG3 criteria for bone disease.
|
Up to 52 months
|
Time to Radiographic Progression
Time Frame: Up to 52 months
|
Time to radiographic progression is defined as time from enrollment to radiographic progression or death due to disease progression, whichever occurs first.
Disease progression is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered progression.
|
Up to 52 months
|
Time to Prostate-Specific Antigen (PSA) Progression
Time Frame: Up to 52 months
|
Time to PSA progression was defined as time from enrollment to the first date of documented PSA progression based on PCWG3 criteria.
A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanograms per milliliter (ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks.
|
Up to 52 months
|
Time to Symptomatic Skeletal Event (SSE)
Time Frame: Up to 52 months
|
Time to SSE was defined as the time from enrollment to first occurrence of one of the following symptomatic skeletal events: tumor-related spinal cord compression, radiation to bone to relieve skeletal symptoms, surgery to bone or need for tumor-related orthopedic surgical intervention, symptomatic or pathologic fracture.
|
Up to 52 months
|
Duration of Objective Response
Time Frame: Up to 52 months
|
Duration of objective response is defined as time from CR or PR to radiographic progression of disease, unequivocal clinical progression or death, whichever occurs first.
Unequivocal clinical progression defined as one or more of following: 1) deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS) to Grade 3 or higher; 2) need to initiate any of following because of tumor progression (even in absence of radiographic evidence of disease): alternative anticancer therapy for prostate cancer, radiation therapy, surgical interventions for complications due to tumor progression.
|
Up to 52 months
|
Number of Participants With Adverse Events (AEs)
Time Frame: Up to 52 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
|
Up to 52 months
|
Number of Participants With Worst Toxicity Grades for Clinical Laboratory Tests Based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Time Frame: Up to 52 months
|
Number of participants with worst toxicity grades for clinical laboratory tests (chemistry and hematology) based on NCI-CTCAE were reported.
The chemistry laboratory parameters were: alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased and the hematology parameters were: hemoglobin increased, lymphocyte count increased.
Grading was done as: Grade 1 (=mild), Grade 2 (=moderate), Grade 3 (=severe) and Grade 4 (=potentially life-threatening).
|
Up to 52 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 31, 2016
Primary Completion (Actual)
January 26, 2021
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
August 1, 2016
First Submitted That Met QC Criteria
August 1, 2016
First Posted (Estimated)
August 3, 2016
Study Record Updates
Last Update Posted (Actual)
September 14, 2023
Last Update Submitted That Met QC Criteria
September 12, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Congenital Abnormalities
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Niraparib
Other Study ID Numbers
- CR108208
- 64091742PCR2001 (Other Identifier: Janssen Research & Development, LLC)
- 2016-002057-38 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
Clinical Trials on Niraparib
-
Tesaro, Inc.Completed
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RecruitingOvarian Cancer | Advanced Solid TumorUnited States
-
Tesaro, Inc.Active, not recruiting
-
Fudan UniversityRecruitingTreatment EfficacyChina
-
Chongqing University Cancer HospitalRecruiting
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProstate AdenocarcinomaUnited States
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Hunan Cancer HospitalUnknown
-
Lei LiRecruitingChemotherapy | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Niraparib | Anlotinib | CA125 | Targeted Therapy | Recurrent Ovarian CancerChina